Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301536 | 0.88 | CYP46A1 (0.42) | MAPTKMT2ATP53 | |
| SCHEMBL1151860 | 0.86 | MAPT (0.32) | MAPTCYP1A2CYP2C19KMT2ATP53 | |
| SCHEMBL1152307 | 0.85 | HTR7 (0.33) | MAPTCYP1A2CYP2C19KMT2A | |
| SCHEMBL1152937 | 0.85 | KMT2A (0.34) | MAPTCYP1A2CYP2C19KMT2A | |
| SCHEMBL1152602 | 0.85 | JAK2 (0.33) | MAPTCYP1A2CYP2C19KMT2A | |
| SCHEMBL1152556 | 0.85 | CYP1A2 (0.33) | MAPTCYP1A2CYP2C19KMT2A | |
| SCHEMBL6296986 | 0.84 | HTR7 (0.35) | MAPTCYP1A2CYP2C19KMT2A | |
| SCHEMBL1153092 | 0.83 | KMT2A (0.36) | MAPTCYP1A2CYP2C19KMT2A | |
| SCHEMBL6295433 | 0.83 | JAK2 (0.32) | MAPTCYP1A2CYP2C19KMT2A | |
| SCHEMBL1152916 | 0.82 | CYP1A2 (0.32) | MAPTCYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023955-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | RODGERS JAMES D (US) | 2004-02-05 | — | — | US | claimed |
| US-6596729-B2 | Especially in combination with one or more HIV reverse transcriptase inhibitors, HIV protease inhibitors, fusion inhibitors, and/or CCR-5 | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | claimed |
| US-20020107261-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-6969721-B2 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB PHARMA (US) | 2005-11-29 | — | — | US | disclosed |
| US-20040023955-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | RODGERS JAMES D (US) | 2004-02-05 | — | — | US | disclosed |
| US-6596729-B2 | Especially in combination with one or more HIV reverse transcriptase inhibitors, HIV protease inhibitors, fusion inhibitors, and/or CCR-5 | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-20020107261-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | MAPT 1583/4885CYP1A2 3895/4885CYP2C19 3439/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | MAPT 1583/4885CYP1A2 3895/4885CYP2C19 3439/4885 |
| US-20040023955-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | TYMP, POLRMT, DPYD | MAPT 1600/4885CYP1A2 403/4885CYP2C19 231/4885 |
| US-20020107261-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | TYMP, POLRMT, DPYD | MAPT 1600/4885CYP1A2 403/4885CYP2C19 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.